Boehringer Ingelheim expanded its strategic push into RNA splicing science by striking a deal worth up to $1 billion with Envisagenics. The collaboration targets precision oncology approaches for solid tumors, aiming to leverage Envisagenics’ platform to identify therapeutic opportunities tied to alternative splicing. Envisagenics’ technology is positioned as enabling researchers to connect patient-relevant molecular states to drug discovery hypotheses, including the ability to find targets that traditional expression-centric methods may miss. The arrangement includes upfront payments, research funding, and milestone-driven components. The agreement underscores how large oncology players are increasingly seeking modality-adjacent, biology-driven innovation rather than only expanding existing target classes.